Clinical data | |
---|---|
Other names | 6-n-propylthiouracil (PROP) |
AHFS/Drugs.com | Monograph |
MedlinePlus | a682465 |
Pregnancy category |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 80%-95% |
Metabolism | ? |
Elimination half-life | 2 hours |
Excretion | ? |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.000.095 |
Chemical and physical data | |
Formula | C7H10N2OS |
Molar mass | 170.23 g·mol−1 |
3D model (JSmol) | |
Melting point | 219 to 221 °C (426 to 430 °F) |
| |
| |
(verify) |
Propylthiouracil (PTU) is a medication used to treat hyperthyroidism.[3] This includes hyperthyroidism due to Graves' disease and toxic multinodular goiter.[3] In a thyrotoxic crisis it is generally more effective than methimazole.[3] Otherwise it is typically only used when methimazole, surgery, and radioactive iodine is not possible.[3] It is taken by mouth.[3]
Common side effects include itchiness, hair loss, parotid swelling, vomiting, muscle pains, numbness, and headache.[3] Other severe side effects include liver problems and low blood cell counts.[3] Use during pregnancy may harm the baby.[3] Propylthiouracil is in the antithyroid family of medications.[4] It works by decreasing the amount of thyroid hormone produced by the thyroid gland and blocking the conversion of thyroxine (T4) to triiodothyronine (T3).[3]
Propylthiouracil came into medical use in the 1940s.[5] It is on the World Health Organization's List of Essential Medicines.[6]